Logo image of ALIKO.PA

IKONISYS SA (ALIKO.PA) Stock Price, Quote, News and Overview

EPA:ALIKO - Euronext Paris - Matif - FR00140048X2 - Common Stock - Currency: EUR

1.56  +0.02 (+1.3%)

ALIKO.PA Quote, Performance and Key Statistics

IKONISYS SA

EPA:ALIKO (5/8/2025, 7:00:00 PM)

1.56

+0.02 (+1.3%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High1.71
52 Week Low1.28
Market Cap21.51M
Shares13.79M
Float6.15M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-19 2021-07-19


ALIKO.PA short term performance overview.The bars show the price performance of ALIKO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8 10

ALIKO.PA long term performance overview.The bars show the price performance of ALIKO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30 -40

The current stock price of ALIKO.PA is 1.56 EUR. In the past month the price increased by 11.43%. In the past year, price increased by 11.43%.

IKONISYS SA / ALIKO Daily stock chart

ALIKO.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABL.DE ABBOTT LABORATORIES 28.2 206.87B
IUI1.DE INTUITIVE SURGICAL INC 71.18 172.45B
BSX.DE BOSTON SCIENTIFIC CORP 38.91 137.55B
2M6.DE MEDTRONIC PLC 15.79 95.77B
SHL.DE SIEMENS HEALTHINEERS AG 20.84 52.90B
BOX.DE BECTON DICKINSON AND CO 11.99 42.93B
EWL.DE EDWARDS LIFESCIENCES CORP 29.24 39.54B
DC4.DE DEXCOM INC 51.58 29.53B
1PHIA.MI KONINKLIJKE PHILIPS NV 16.09 21.02B
PHIA.AS KONINKLIJKE PHILIPS NV 15.97 20.42B
PHI1.DE KONINKLIJKE PHILIPS NV 15.48 20.23B
BIM.PA BIOMERIEUX 30.18 13.79B

About ALIKO.PA

Company Profile

Ikonisys SA specializes in the design, manufacture, and distribution of cellular diagnosis applications for cancer, genetic diseases, and fertility problems. The company is headquartered in Paris, Ile-De-France and currently employs 10 full-time employees. The company went IPO on 2021-07-19. The firm offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. The company utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. The company includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.

Company Info

IKONISYS SA

62 Rue De Caumartin, Paris 9

Paris ILE-DE-FRANCE FR

Employees: 10

ALIKO Company Website

ALIKO Investor Relations

IKONISYS SA / ALIKO.PA FAQ

What is the stock price of IKONISYS SA today?

The current stock price of ALIKO.PA is 1.56 EUR. The price increased by 1.3% in the last trading session.


What is the ticker symbol for IKONISYS SA stock?

The exchange symbol of IKONISYS SA is ALIKO and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALIKO.PA stock listed?

ALIKO.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for IKONISYS SA stock?

9 analysts have analysed ALIKO.PA and the average price target is 4.18 EUR. This implies a price increase of 168.08% is expected in the next year compared to the current price of 1.56. Check the IKONISYS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IKONISYS SA worth?

IKONISYS SA (ALIKO.PA) has a market capitalization of 21.51M EUR. This makes ALIKO.PA a Nano Cap stock.


How many employees does IKONISYS SA have?

IKONISYS SA (ALIKO.PA) currently has 10 employees.


What are the support and resistance levels for IKONISYS SA (ALIKO.PA) stock?

IKONISYS SA (ALIKO.PA) has a support level at 1.56 and a resistance level at 1.6. Check the full technical report for a detailed analysis of ALIKO.PA support and resistance levels.


Should I buy IKONISYS SA (ALIKO.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IKONISYS SA (ALIKO.PA) stock pay dividends?

ALIKO.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of IKONISYS SA (ALIKO.PA)?

IKONISYS SA (ALIKO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).


ALIKO.PA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ALIKO.PA. When comparing the yearly performance of all stocks, ALIKO.PA is one of the better performing stocks in the market, outperforming 81.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALIKO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALIKO.PA. Both the profitability and financial health of ALIKO.PA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALIKO.PA Financial Highlights

Over the last trailing twelve months ALIKO.PA reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -6.92% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -10.87%
ROE -14.41%
Debt/Equity 0.1
Chartmill High Growth Momentum
EPS Q2Q%-34.48%
Sales Q2Q%130.8%
EPS 1Y (TTM)-6.92%
Revenue 1Y (TTM)14.59%

ALIKO.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALIKO.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners54.05%
Ins Owners2.61%
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target4.18 (167.95%)
EPS Next Y-16.25%
Revenue Next Year0%